Testing E6742 in Systemic Lupus Erythematosus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with SLE for at least 6 months before enrollment
- Currently experiencing moderate to severe lupus activity in at least one organ system
- Already taking at least one standard lupus medication (steroids, hydroxychloroquine, or immunosuppressants) at a stable dose
- Willing to use effective birth control if you can become pregnant
- No serious infections, tuberculosis, liver disease, or heart rhythm problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral tablet for people with systemic lupus erythematosus. It aims to see if the new medicine can help reduce lupus symptoms when added to your current standard treatment. Participants will receive the study drug and be monitored closely.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.